|
|
Post by coco on Sept 28, 2015 12:12:55 GMT -5
We all feel a little uneasy, to say the least but if you've done your dd then there is no question.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 28, 2015 12:21:41 GMT -5
Two certainties: MannKind will not go bankrupt because Al will not allow that and scripts will continue to grow. From these two certainties the downside a few $ while the upside is much greater.
|
|
|
|
Post by harrys on Sept 28, 2015 12:37:18 GMT -5
I think everyone can agree (including those short, maybe in private) that if it was all about the science, and efficacy translated into a linear rise in valuation, then MNKD would have a multi-billion $ market cap right now. As far as doing your DD, at this point MNKD isn't about the science of Afrezza, it's a story about Wall Street. I've seen other truly amazing drugs crushed by Wall Street and big pharma, I find no solace in the science argument anymore. It's all about management and execution. My ambiguous conclusion, things can go either way at this point.
|
|
|
|
Post by bradleysbest on Sept 28, 2015 12:55:24 GMT -5
This (MNKD investment) was a rude awakening for me in how corrupt Wall Street is.......
|
|
|
|
Post by biotec on Sept 28, 2015 13:07:05 GMT -5
This (MNKD investment) was a rude awakening for me in how corrupt Wall Street is....... Why blame Wall Street? You don't think it has to do with the piss poor script count? I think its all to do with the script's. |
|
|
|
Post by jonesq on Sept 28, 2015 13:17:51 GMT -5
I think what we saw today was another short attack. They were trying to take the stock below $3.00 thereby triggering stop loss orders. Fortunately, we didn't dip below $3.00 today. If it does dip below $3, after a bunch of selling off, that would be a good time to buy more.
|
|
|
|
Post by Chris-C on Sept 28, 2015 13:19:43 GMT -5
This (MNKD investment) was a rude awakening for me in how corrupt Wall Street is....... Too bad more people in the population have not had that "awakening" yet. The first step to recovery is acknowledging we have a problem. |
|
|
|
Post by harrys on Sept 28, 2015 13:28:59 GMT -5
I think what we saw today was another short attack. They were trying to take the stock below $3.00 thereby triggering stop loss orders. Fortunately, we didn't dip below $3.00 today. If it does dip below $3, after a bunch of selling off, that would be a good time to buy more. What we're seeing today can hardly be considered an attack on MNKD specifically, the usual shenanigans today are magnified 10x with the crash in biotech currently taking place. I wonder when Shkrelli designed this if he had any thought toward MNKD in particular. No doubt he'll have the last laugh with millions made over the last week or so. If he ever gets his justice, it'll mean we have a progressive in the White House. |
|
|
|
Post by _neil on Sept 28, 2015 13:29:10 GMT -5
This (MNKD investment) was a rude awakening for me in how corrupt Wall Street is....... Why blame Wall Street? You don't think it has to do with the piss poor script count? I think its all to do with the script's. I am with biotec on this. Wall street corruption is a non-starter as far as arguments go. No long would be pointing fingers at wall street if the pps was at an absurd multiple of sales -like 30$, let's say. Simply put, the blame lies on the doorstep of Hakan/Pfeffer and Mann. The former pair for their piss-poor management and the latter for protecting them for whatever reason instead of hiring someone right for the job. Then again, if Mann is purely interested in bringing the product to market at whatever cost, his nobility is admired but I feel swindled for unknowingly being part of a charity when I thought I was in it for profits. My faith in data/dd led me to fix an (artificial) deadline for the end of the year to hold this stock. Now that we are getting close to that mark, I probably will rip off the bandage sooner.
Sorry for the rant. |
|
|
|
Post by Chris-C on Sept 28, 2015 13:30:08 GMT -5
This (MNKD investment) was a rude awakening for me in how corrupt Wall Street is....... Why blame Wall Street? You don't think it has to do with the piss poor script count? I think its all to do with the script's. Seriously? There are pharma stocks with market caps that are multiples of Mannkind who don't have approved drugs yet. Their script numbers are thus zero. The scripts don't help, for sure, but to deny the street games being played with this stock is to be denying reality. Check out the number of times MNKD has been on the REG SHO list. The manipulation is driven by hedge funds, day trading "momentum traders" piling on, investment 'snakes' who shill for short sided interests, and a massive short position that is made worse by naked shorting and SEC indifference. And one more thing...in case you forgot, Mannkind partnered with Sanofi to market Afrezza. The ball is in their court. Many of us, recognizing the situation, are giving Sanofi time to do their work. Blaming the MNKD executive team for Afrezza sales is inappropriate, IMO. Their responsibility is cartridge production, and they have been executing in that realm. |
|
|
|
Post by biotec on Sept 28, 2015 13:40:26 GMT -5
Why blame Wall Street? You don't think it has to do with the piss poor script count? I think its all to do with the script's. Seriously? There are pharma stocks with market caps that are multiples of Mannkind who don't have approved drugs yet. Their script numbers are thus zero. The scripts don't help, for sure, but to deny the street games being played with this stock is to be denying reality. Check out the number of times MNKD has been on the REG SHO list. The manipulation is driven by hedge funds, day trading "momentum traders" piling on, investment 'snakes' who shill for short sided interests, and a massive short position that is made worse by naked shorting and SEC indifference. And one more thing...in case you forgot, Mannkind partnered with Sanofi to market Afrezza. The ball is in their court. Many of us, recognizing the situation, are giving Sanofi time to do their work. Blaming the MNKD executive team for Afrezza sales is inappropriate, IMO. Their responsibility is cartridge production, and they have been executing in that realm. The Friday we see a huge up tic in scripts will be the time we see the PPS shot up. Do you blame the shorts since Feb? with 500 or less scripts a week! I wish I made as much$ as shorts this summer.
|
|
|
|
Post by notamnkdmillionaire on Sept 28, 2015 13:45:37 GMT -5
This (MNKD investment) was a rude awakening for me in how corrupt Wall Street is....... Mannkind didn't do itself any favors either. The delay is in big part due to Management miscues too. MNKd isn't an innocent bystander in what we are now witnessing. |
|
|
|
Post by _neil on Sept 28, 2015 13:54:25 GMT -5
I wouldn't even be that concerned about the script counts if it weren't for the poor communication of their plans and metrics for progress. I assume MNKD management (and the part of SNY that forms the committee for Afrezza) sees themselves as some biotech version of Apple with their super secret launch plans while they are barely equivalent to a Blackberry. No competitor is scared of them at this point. No ads, no known sales team, no attempt to educate the general diabetic population. SNY cannot be blamed even if this is a completely malicious partnership from their end. At least they are shutting down a potential market disruptor for very little money and protecting their own shareholders. MNKD on the other hand is just taking the beating lying down and taking the retail longs for a disastrous ride.
|
|
|
|
Post by mssciguy on Sept 28, 2015 13:55:33 GMT -5
This (MNKD investment) was a rude awakening for me in how corrupt Wall Street is....... Mannkind didn't do itself any favors either. The delay is in big part due to Management miscues too. MNKd isn't an innocent bystander in what we are now witnessing. You are very polite and fair in your assessment. They way I would put it, is this: Goldman Sachs and BofA are not a Milburn Drysdale, and Al Mann is not a Jed Clampett (with a genius engineering background). They all sip mint juleps together at the cement pond from time to time, with all those other critters. Would make a great modern Sherlock Holmes short story, some day, maybe too close to home though. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 28, 2015 13:55:51 GMT -5
Why blame Wall Street? You don't think it has to do with the piss poor script count? I think its all to do with the script's. Seriously? There are pharma stocks with market caps that are multiples of Mannkind who don't have approved drugs yet. Their script numbers are thus zero. The scripts don't help, for sure, but to deny the street games being played with this stock is to be denying reality. Check out the number of times MNKD has been on the REG SHO list. The manipulation is driven by hedge funds, day trading "momentum traders" piling on, investment 'snakes' who shill for short sided interests, and a massive short position that is made worse by naked shorting and SEC indifference. And one more thing...in case you forgot, Mannkind partnered with Sanofi to market Afrezza. The ball is in their court. Many of us, recognizing the situation, are giving Sanofi time to do their work. Blaming the MNKD executive team for Afrezza sales is inappropriate, IMO. Their responsibility is cartridge production, and they have been executing in that realm. Sanofi is a capable partner. Perhaps not the best sales, marketing & regulatory machine in the world of big pharma but certainly capable. Weekly NRx needs to start to show some consistent growth and hopefully the start of this was last weeks number. If not, I would think by the end of October at the latest. Without NRx growth, we can only hope (and the only thing that would drive share price) that they are working on an improved label, launch in another country while MNKD works on landing a Technosphere deal or two. If not these things to drive share price, there could be one other thing... And for those of you thinking Al no longer cares about share price, don't kid yourself. He has been at this since 1999 with nearly $1B of his own coin into MNKD. His legacy is to leave a lot of money to the entities that will continue to do research and create products to help mankind. His goal is not to leave the $1B he started with to his foundation(s) but a number many times greater. PS - all the social media from Sam and others telling of how well Afrezza has worked for them has helped to take away doubts about the efficacy of Afrezza. A product that is more predictable, reduces hypos significantly, reduces A1c, easy to use, better quality of life for the patient and a massive reduction in long term health complications. All of this for a company with a market cap below $1.5B and Technosphere to boot. |
|
